Tagged with MENA

Morocco Morocco is undergoing ambitious reforms, extending universal healthcare coverage to all its citizens while resolving the shortcomings laid bare during the COVID-19 pandemic. Endorsed by a USD 450 million Program-for-Results loan from the World Bank, the government’s plans have been well received by the country’s healthcare and life sciences stakeholders…

Morocco Senior director and general manager for North, East & West Africa at IQVIA Hocine Mahdi discusses the positive aspects of Morocco’s healthcare landscape and the challenges that remain for multinational companies looking to enter the market, particularly within the context of HTA. Moreover, he outlines the firm’s strategy across African…

UAE Globally, while there is broad stakeholder alignment on topics like clinical trials and innovation, there is real divergence in approaches to pharmacoeconomics and health technology assessment (HTA). This is perhaps in part due to the differences between systems like those in Europe where these functions are state mandates and those,…

Morocco Salim El Guermaï of leading Moroccan generics manufacturer Galenica outlines how, in the past three years, the firm played a key role in Morocco’s COVID-19 pandemic response, continued to serve Moroccan patients with essential medicines, and bolstered the country’s standing as a pharmaceutical hub for the African continent.    Our…

Morocco As North Africa cluster lead Pfizer veteran Diego Forero heads up Morocco, Tunisia, Libya, and Algeria in addition to being the country manager for Morocco. He describes the company’s 57-year presence and its local manufacturing site that produces almost 70 percent of Pfizer’s medicines marketed in Morocco as well as…

Morocco CEO Mia Lahlou-Filali walks us through Pharma 5’s commitment to “Made in Morocco” generics, an approach that has led the company to represent one third of the country’s generics market. She also explains the family-owned firm’s expansion efforts outside of Morocco that include a factory in the Ivory Coast, a…

Morocco Driss Chaoui outlines recent milestones in Afric-Phar’s over 50-year history, including the launch of its first in-house developed generic, and discusses the firm’s unique focus on orphan and rare diseases and the challenges facing the field in Morocco. He also reviews the opportunities presented by the transformation of Morocco’s regulatory…

Morocco Three years on from his last PharmaBoardroom interview, Karim Lahlou highlights the evolution of Moroccan pharma manufacturer Iberma as it expands its activities from solely in-licensing to developing and selling its own products, growing its global partnership base, and looking to penetrate international markets while leveraging the growing reputation of…

Morocco DHL’s Tina Manoukian lays out how the global logistics giant helped ensure the safe and timely distribution of medicines and vaccines during the COVID-19 pandemic, outlines the scope and scale of DHL operations in Morocco, and explains why the country is well positioned to become a distribution and logistics hub…

UAE From humble origins, taiba can now count on a unique two decades of experience in bringing innovative rare disease products to patients across the MENA region. The Dubai headquartered company, now branding itself as the partner of choice for rare diseases across the region, has also moved to create a…

UAE Thanks to favourable regulations from the Ministry of Health and Prevention (MoHaP) which include fast-track regulatory pathways, patients in the UAE are gaining access to innovative medicines in similar time frames to their counterparts in the US and Europe, in some cases even ahead. Against this backdrop, the representatives of…

UAE As the UAE’s only gastrointestinal oncologist, Professor Humaid Al-Shamsi is well-placed to comment on the evolution of cancer care in the country, noting massive leaps forward in terms of technology, patient experience, and regulatory timelines. Looking forward, Professor Al-Shamsi calls for even greater investment into oncology R&D programs as the…